{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:32Z","timestamp":1789469132414,"version":"build-2803163510"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Spleen volume is commonly assessed in clinical trials involving patients with myelofibrosis (MF), but direct measurement requires radiologic imaging. In routine clinical settings, spleen length measured by palpation is frequently used as an alternative measure. As the relationship between spleen length and spleen volume is not strictly proportional, interpretation of palpation-based measurements may be variable. In this post hoc analysis, we examined the relationship between palpable spleen length and spleen volume in patients with MF using pooled data from two phase 3 clinical studies. Palpable spleen length and patient weight, height, age, and sex were evaluated using mixed-model regression to identify variables associated with spleen volume. A regression model incorporating palpable spleen length and patient height provided the best fit for predicting spleen volume. The model presented here defines a quantitative relationship between palpable spleen length and spleen volume and provides a standardized reference for relating these measurements in research and observational contexts.<\/jats:p>","DOI":"10.1007\/s00277-026-07108-8","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:54:14Z","timestamp":1781121254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A model to estimate spleen volume from palpated spleen length in patients with myelofibrosis"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3705-0585","authenticated-orcid":false,"given":"Albert","family":"Assad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Erickson-Viitanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Hamer-Maansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5072-7636","authenticated-orcid":false,"given":"Evan","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langmuir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"13","key":"7108_CR1","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"11","key":"7108_CR2","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s00277-020-04055-w","volume":"99","author":"S Verstovsek","year":"2020","unstructured":"Verstovsek S, Yu J, Kish JK, Paranagama D, Kaufman J, Myerscough C, Grunwald MR, Colucci P, Mesa R (2020) Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. Ann Hematol 99(11):2555\u20132564. https:\/\/doi.org\/10.1007\/s00277-020-04055-w","journal-title":"Ann Hematol"},{"issue":"20","key":"7108_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"9","key":"7108_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr., Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"7","key":"7108_CR5","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00277-020-04069-4","volume":"99","author":"D Tremblay","year":"2020","unstructured":"Tremblay D, Schwartz M, Bakst R, Patel R, Schiano T, Kremyanskaya M, Hoffman R, Mascarenhas J (2020) Modern management of splenomegaly in patients with myelofibrosis. Ann Hematol 99(7):1441\u20131451. https:\/\/doi.org\/10.1007\/s00277-020-04069-4","journal-title":"Ann Hematol"},{"issue":"8","key":"7108_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.clml.2017.05.015","volume":"17","author":"CB Miller","year":"2017","unstructured":"Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S (2017) Practical measures of clinical benefit with ruxolitinib therapy: an exploratory analysis of COMFORT-I. Clin Lymphoma Myeloma Leuk 17(8):479\u2013487. https:\/\/doi.org\/10.1016\/j.clml.2017.05.015","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07108-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07108-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07108-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:45Z","timestamp":1789465365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07108-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":6,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7108"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07108-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The COMFORT-I (NCT00952289) and LIMBER-313 (NCT04551066) trials were conducted in accordance with the Declaration of Helsinki and the guidelines for Good Clinical Practice. The protocols were approved by each participating site\u2019s institutional review board.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent.","order":2,"name":"Ethics","label":"Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AA, SE-V, JEH-M, EB, and PL are employees and shareholders of Incyte Corporation.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"382"}}